Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits. It focuses on the exploration and development of Skaergaard project located in Southeast Greenland and the Sarartoq neodymium-praseodymium (Nd-Pr) rare earths project in Southwest Greenland. The company is also involved in the development of KLTO-202, a gene therapy for the treatment and prevention of amyotrophic lateral sclerosis; and KLTO-101 for the treatment or prevention of Alzheimer's disease, as well as therapies to treat Parkinson's and other age-related disorders. The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026. Greenland Mines Ltd is based in Charlotte, North Carolina.
Research context
GRMLW appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
No comments yet
Start a focused discussion about GRMLW.